Advertisement


Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

2024 ASCO Annual Meeting

Advertisement

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the dynamic is a randomized trial looking at the utility of using CtDNA to guide adjuvant treatment in stage two colon cancer. The rationale behind the study is the fact that the role of adjuvant chemotherapy remains debatable in stage two colon cancer where surgery cured the majority of patients and to date, there has been very little evidence of survival benefit with the use of adjuvant chemotherapy. Our prior work have shown that detection of CtDNA after surgery is highly prognostic, where almost all patient recurred if left untreated. So this is a non-inferiority study that randomized patient to two-thirds receiving CtDNA guided management and one-third of standard management. So in the CtDNA guided group, patient with a positive result after surgery receive adjuvant chemotherapy and patient with a negative result were just observed. So the key findings from the study is that we have reduced the use of adjuvant chemotherapy by using CtDNA compared to standard management from 28% down to 15%, but we did not compromise recurrence-free survival. The updated results from dynamics showed that even at 5 years, the recurrence-free survival was 88.3% in the CtDNA guided group, and 87.2% with that of management of not using the blood test and the lower bound of the 95 confidence interval remains above the non-inferiority margin, again, confirming the non-inferiority of this approach. The overall survival between the two arms are similarly very favorable, ranging around 93%, which is very impressive. Intriguingly, we found that more than half the patient, substantial proportion of the death events in the study were not due to colorectal cancer recurrence resulting in a disease-specific survival, exceeding 97% across both arms. Another interesting finding is that we collected serial bloods on patient who have CtDNA positive and receive adjuvant chemotherapy. We found a very high clearance rate of 87.5% of CtDNA clearance following adjuvant chemotherapy, and patients who cleared a CtDNA had exceedingly good recurrence-free survival compared to patient who did not clear their CtDNA. So we also found that in untreated CtDNA negative T4 tumor, their overall survival is excellent at 19.6%. The implication for clinical practice is that using CtDNA to guide therapy compared to not having the blood test in stage two colon cancer can reduce the use of adjuvant chemotherapy without compromising patient's outcome and that CtDNA clearance rate is very high, supporting the benefit of adjuvant chemotherapy in this very high-risk population.

Related Videos

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Breast Cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.

Pancreatic Cancer

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Advertisement

Advertisement




Advertisement